Active n = 30 | Placebo n = 28 | p value | |
---|---|---|---|
Age (years) | 68.1 ± 5.9 | 69.2 ± 6.3 | 0.35 |
Male/female ratio | 12/18 | 11/17 | 0.45 |
Duration of rhinitis (years) | 4.4 ± 1.4 | 6.9 ± 2.1 | 0.23 |
Number of subjects with asthma | 0 | 0 | – |
Number of patients with eczema | 2 | 1 | 0.21 |
Number of smokers | 6 | 5 | 0.67 |
Number of patients with stable coronary disease | 8 | 10 | 0.17 |
Number of patients with arterial hypertension | 12 | 9 | 0.22 |
Number of patients with diabetes | 4 | 5 | 0.39 |
Mean weekly nasal symptom score | 3.21 ± 0.93 | 3.11 ± 0.54 | 0.18 |
Mean weekly non-nasal symptom score | 3.64 ± 0.55 | 3.21 ± 0.9 | 0.11 |
Mean weekly medication score | 0.45 ± 0.17 | 0.51 ± 0.09 | 0.59 |
Total IgE | 187.43 ± 64.01 | 201.9 ± 83.22 | 0.19 |
Specific IgE to Der p (kU/l) | 24.9 ± 10.11 | 27.31 ± 13.9 | 0.4 |
Specific IgE to Der f (kU/l) | 17.45 ± 8.31 | 15.9 ± 10.5 | 0.19 |